Abstract:Background Genetic and environmental factors contribute to the pathogenesis of schizophrenia (SZ) and bipolar disorder (BD). Among genetic risk groups stratified by combinations of Polygenic Risk Score (PRS) deciles for SZ, BD and SZ versus BD, genetic SZ risk groups had high SZ risk and prominent cognitive impairments. Furthermore, epigenetic alterations are implicated in these disorders. However, it was unclear whether DNA Methylation Risk Scores (MRSs) for SZ risk derived from blood and brain tissues were associated with SZ risk, particularly the PRS-stratified genetic SZ risk group. Methods Epigenome-wide association studies (EWASs) of SZ risk in whole blood were preliminarily conducted between 66 SZ patients and 30 healthy controls (HCs) and among genetic risk groups (individuals with low genetic risk for SZ and BD in HCs (n=30) and in SZ patients (n=11), genetic BD risk in SZ patients (n=25) and genetic SZ risk in SZ patients (n=30)) stratified by combinations of PRSs for SZ, BD and SZ versus BD. Next, differences in MRSs based on independent EWASs of SZ risk in whole blood, postmortem frontal cortex (FC) and superior temporal gyrus (STG) were investigated among our case-control and PRS-stratified genetic risk status groups. Results Among case-control and genetic risk status groups, 33 and 351 genome-wide significant differentially methylated positions (DMPs) associated with SZ were identified, respectively, many of which were hypermethylated. Compared with the low genetic risk in HCs group, the genetic SZ risk in SZ group had 39 genome-wide significant DMPs, while the genetic BD risk in SZ group had only six genome-wide significant DMPs. The MRSs for SZ risk derived from whole blood, FC and STG were higher in our SZ patients than in HCs in whole blood and were particularly higher in the genetic SZ risk in SZ group than in the low genetic risk in HCs and genetic BD risk in SZ groups. Conversely, the MRSs for SZ risk based on our whole-blood EWASs among genetic risk groups were also associated with SZ in the FC and STG. There were no correlations between the MRSs and PRSs. Conclusions These findings suggest that the MRS is a potential genetic marker in understanding SZ, particularly in patients with a genetic SZ risk.

Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients

DNA Methylation in Schizophrenia: Progress and Challenges

Genome-wide DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia in the Chinese Han population

DNA Methylation Differences in Cortical Grey and White Matter in Schizophrenia.

Schizophrenia is associated with altered DNA methylation variance

Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia.

Genome-wide analysis of DNA methylation in 106 schizophrenia family trios in Han Chinese

Hyper-Coordinated DNA Methylation is Altered in Schizophrenia and Associated with Brain Function

The association of DNA methylation and brain volume in healthy individuals and schizophrenia patients

Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples

Identification of Schizophrenia-Associated Loci by Combining DNA Methylation and Gene Expression Data from Whole Blood

An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation

Methylation Patterns in Whole Blood Correlate with Symptoms in Schizophrenia Patients.

DNA Methylation Meta-Analysis Reveals Cellular Alterations in Psychosis and Markers of Treatment-Resistant Schizophrenia

Large-scale analysis of DNA methylation identifies cellular alterations in blood from psychosis patients and molecular biomarkers of treatment-resistant schizophrenia

Integrating brain methylome with GWAS for psychiatric risk gene discovery

Cell type‐specific DNA methylation analysis of the prefrontal cortex of patients with schizophrenia

Genome-wide DNA Methylation Analysis in Families with Multiple Individuals Diagnosed with Schizophrenia and Intellectual Disability.

DNA Methylation and Schizophrenia: Current Literature and Future Perspective

Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder

Genome-wide methylome analyses reveal novel epigenetic regulation patterns in schizophrenia and bipolar disorder